. .
Sponsor and exhibitor information
Hall Plan

Hallenplan Biomedica 2017

Day 1 // Session 1, Blauwe Zaal

Smart Diagnostics

Dr. Francy Crijns

Dr. Francy Crijns (Chairman)

Zuyd University of Applied Sciences, NL

Senior Lecturer & Researcher

Curriculum vitae

Dr. Francy Crijns was born in 1967 in Genk (Belgium). She studied Biology at the University of Louvain and received her Master’s Degree in 1989. Partially overlapping with her Masters study, she obtained a teaching certification in 1990. She attained a Ph.D. degree in Biology (2000) where she studied the functional and structural determinants of vascular dysfunction in experimental diabetes at the Maastricht University. Since 1998, she has been affiliated with Zuyd University of Applied Sciences in Heerlen (the Netherlands) where she coordinated the educational program Biology and Medical Laboratory Research (BML) and performed several management positions. The last few years she concentrates on applied research on antimicrobial coatings and efficacy testing, integrating multidisciplinary research within educational programs at Zuyd. She is the chairman of the EU-COST Action AntiMicrobial Coating Innovations (AMiCI; CA15114), project leader of several antimicrobial research projects and supervisor of bachelor students in their research projects. She is a dedicated board member of the  the SME network organization LifeTecZone and member of the program committee of Biomedica Summit since 2015.

Patrick van de Poel

13:30 - Can Titanium Dioxide coatings help in our battle against nosocomial infections and multi drug resistant microorganisms

Patrick van de Poel

Zuyderland, NL

Infection Control Specialist & Risk Management

Curriculum vitae

since 2015
involved with the subject Nanotech-coatings with Titanium dioxide in healthcare facilities

since 2005
HIP Hygiene advice & Infection Prevention

since 1999
Infection control specialist

since 1999
Zuyderland Medical Centre, Netherlands

1991 - 1999 Operation Theatre nurse

1986 - 1991 Nurse

Working in the field of:

  • Hospitals such as Zuyderland MC (General 900 bed hospital with 2 locations, Geleen and Heerlen)
  • Other hospitals
  • Nursing homes
  • Private clinics
  • Medical industry
  • Educational programs in healthcare
  • National and international symposia and congresses

Specialties in Infection control:

  • CAUTI (Catheter Associated Urine Tract Infections)
  • SSI (Surgical Site Infections) and chronical wound infections
  • BSI (Blood Stream Infections)
  • Infection control in Operation theatre, Emergency room, Hemodialysis, Central Sterilization unit, Cleanroom environment and Cleaning companies



Nosocomial infections occur in healthcare, even in developed countries. Worldwide more people die of infections (including nosocomial infections), than of other diseases or accidental deaths.
Also there is a worldwide growing problem with Multi Drug Resistant micro-organisms. These micro-organisms no longer respond to regular antibiotics. Moreover no new antibiotics are being developed. This means that in nearby future people more people will die of complex infections (also nosocomial infections) or simple infections, which up till now we could easily treat.
Basic hygiene measures and surface cleaning/disinfection work well to reduce the risk of growth and spreading of (multi drug resistant) micro-organisms. However:

  • Compliance is rather low (30-50%)
  • With every treatment of patients, dirty hands (not cleaned or disinfected) or used protection gloves make contact with clean surroundings for at least 4-5 times
  • In Dutch healthcare facilities there are difficult issues in rules and legislation regarding possibilities and products for surface disinfection

Nanotech coatings might be a solution to reduce the risk and fill in the gaps as an additional system to the basic hygiene measures and possible lack of adequate cleaning/ disinfection.

In Vitro several coatings work. The RAAK-study now being performed is to find out objectively if these coatings also work in vivo in healthcare facilities.

  1. Are they bactericidal and virucidal within an acceptable time limit,
  2. Do they ease the cleaning process
  3. Do coatings have a (negative) effect on compliance of basic hygiene measures and regular cleaning
  4. Is disinfection still necessary if coating are being applied to surfaces like medical equipment and surfaces that are being touched with uncleaned/ not disinfected hands or used protection gloves
13:40 - Antimicrobial coatings in healthcare

Lutz Gradewald

NADICO Technologie GmbH, DE

Head Application Engineering

Guus Simons

13:50 - Multiplex PCR detection of bacteria: Syndromic based diagnostics

Guus Simons

PathoFinder B.V., NL


Curriculum vitae

Before founding PathoFinder, Guus Simons worked for eleven years at Keygene, Wageningen, The Netherlands, where he held positions as project manager and business manager and for nine years as project leader at the Netherlands Institute for Dairy Research. He performed his post-doc period at the University of Ghent, Belgium after he got his Ph.D. in molecular biology at the University of Nijmegen, The Netherlands. Guus Simons has written more than 50 peer reviewed papers and 15 patent applications.


PathoFinder is a privately owned diagnostics company based in Maastricht, the Netherlands.

PathoFinder has developed a proprietary technology platform enabling syndromic infectious disease molecular testing. It addresses the three major drivers in infectious disease testing: ease of use, speed and cost-effectiveness. PathoFinder is ISO13485 certified and all products comply to the European IVD directive.

Products comprise panels against respiratory tract infections (22 pathogens consisting of viruses and bacteria), gastro intestinal infections (18 pathogens consisting of viruses, bacteria and parasites), central nervous system infections (22 pathogens consisting of viruses, bacteria and fungi), sexual transmitted disease infections (10 pathogens consisting of bacteria, parasites, viruses and resistance markers) and cervival cancer screening (Human Papilloma Virus typing of high and low risk genotypes). Leading hospitals in Europe are using products of PathoFinder in their routine diagnostic setting.

Dr. Bart van Grinsven

14:00 - Heat Transfer Method, a new method to detect bacteria

Dr. Bart van Grinsven

Maastricht Sciences Programme, NL

Assistant Professor

Curriculum vitae

Assistant Professor Dr. Bart van Grinsven received a master’s degree in bioelectronics and nanotechnology from Hasselt University in 2007. Then he was employed by TNO as a development engineer and returned to the BIOSensor group of Hasselt University in 2008. He successfully defended his PhD in physics in July 2012, promoted by Prof. Dr. Patrick Wagner and Prof Dr. Michael Schöning. After working as a postdoctoral researcher in the same group, he switched to Maastricht University, within the Maastricht Science Programme where he now holds the position of Assistant Professor under the supervsion Prof. Dr. Thomas Cleij. Currently, he has published over 40 peer reviewed articles and is an inventor on 8 patents. Furthermore, he was awarded 4 scientific awards and was nominated for 1 industrial award: (1) Best presentation award (2012) Engineering of Functional Interfaces Session: Biophysics and Medical Physics; (2) Young Scientist Award (2013) Belgian Physical Society; (3) Mckinsey Award (2013) Scientific Award Mckinsey & Company and the FWO; (4) Edmond Hustinx Award for Science (2016) Edmond Hustinx Foundation; (5) AMA Innovation Award (2017) AMA Association for Sensors and Measurement Technology. Dr van Grinsvens’ field of interest includes biosensor development, PoC testing and biomedical device engineering.


In this presentation we would like to introduce a novel bacterial identification assay based on thermal wave analysis through surface imprinted polymers (SIPs). Aluminum chips are coated with SIPs, serving as synthetic cell receptors that have been combined previously with the heat-transfer method (HTM) for the selective detection of bacteria [1]. In this work, the concept of bacterial identification is extended toward the detection of nine different bacterial species. In addition, a novel sensing approach, thermal wave transport analysis (TWTA), is introduced, which analyzes the propagation of a thermal wave through a functional interface.

The results presented here demonstrate that bacterial rebinding to the SIP layer resulted in a measurable phase shift in the propagated wave. In this way, the sensor is able to selectively distinguish between the different bacterial species used in this study. Furthermore, a dose−response curve was constructed to determine a limit of detection of 1 × 10^4 CFU mL−1, indicating that TWTA is advantageous over HTM in terms of sensitivity and response time. Additionally, the limit of selectivity of the sensor was tested in a mixed bacterial solution, containing the target species in the presence of a 99-fold excess of competitor species. Finally, a first application for the sensor in terms of infection diagnosis is presented, revealing that the platform is able to detect bacteria in clinically relevant concentrations as low as 3 × 10^4 CFU mL−1 in spiked urine samples [2].

Gabrielle Tuijthof

14:10 - LIME – a Kennis-As project on measurements in healthcare - What’s in it for you?

Gabrielle Tuijthof

Zuyd University of Applied Sciences, NL

Lector Smart Devices

Curriculum vitae

Gabrielle Tuijthof was born in Teheran, Iran, in 1975. She graduated cum laude in Mechanical Engineering (MSc degree) at the Delft University of Technology (TU Delft) in 1998. She performed her PhD within the ‘Minimally Invasive Surgery and Interventional Techniques’ program at TU Delft in close cooperation with the Dept. of Orthopedic Surgery, Academic Medical Centre, Amsterdam. From 2003 until now she remains affiliated at AMC, where she worked in various research projects including her VENI-grant (2004). From 2006-2012 she was assistant professor and from 2012-2016 she was associate professor at TU Delft with the focus on optimization of the surgical performance of arthroscopic techniques via government funded projects Healing Water (STW), Steerable Punch (ZonMW), Vibrant Vision (STW), and Compliant Needle (ASPASIA). Additionally, she was director of education of the new bachelor program Clinical Technology, which is a joint degree program develop within the Medical Delta. She has over 65 peer reviewed publications. In 2016, Gabrielle was appointed as lector Smart Devices at Zuyd University of Applied Sciences with a focus on the development and implementation of wearables, point of care devices and devices that stimulate healthy lifestyle. She is one of the project leaders of the Kennis-As program LImburg MEasures (LIME).


In the domain of healthcare, patients are diagnosed, monitored and followed up with all types of measurements ranging from questionnaires, to blood tests, heart monitoring and medical imaging. With the increase in the capabilities of technological platforms, the amount of medical data is increasing to cope with the complexity of our human body and obtain full insight in the health status of a patient and to monitor the quality of healthcare. Also, the increase in measurements does not necessary contribute to new insights or improved patient care, because devices lack required quality and validity, do not fit in the medical workflow, do not provide meaningful feedback or offer an overload of information that is too complex to interpret.

LIME (LImburg MEasures) aim is to stimulate meaningful measurements in healthcare by acting as a central hub that brings together key stakeholders including universities (Zuyd Hogeschool, Maastricht University), hospitals, healthcare facilities, industry, patients and centres of expertise.

LIME will facilitate smarter and efficient healthcare measurements in co-creation with professionals and students in an open innovation network. To this end a digital portal is offered (Meetpunt) where any type of questions regarding measurements in healthcare can be posed by anybody, execute in-depth knowledge development in flagship projects, coach start-ups and accelerate business in demonstrators projects, offer Living labs in which usability tests are performed and innovate education of future professionals adapted to the rapid developments in healthcare measurement.

Birgit Teunissen

14:20 - Assay development for hygiene monitoring and efficacy testing of antimicrobial coatings

Birgit Teunissen

Chemelot Innovation & Learning Labs, NL

Business Developer

Curriculum vitae

Birgit is a molecular biologist with a broad experience in both academic and applied research, teaching and business development. She holds a master in Biological Health Sciences (1999, University of Maastricht) and a PhD in Molecular Biology (2004, University of Utrecht). From 2004 till 2007 Birgit worked as a postdoc at the Maastricht University. End 2007 she started at Zuyd University of Applied Sciences as a lecturer-researcher. Since 2008 Birgit was occupied with the setup of a program for applied research. She has established partnerships with multiple partners from industry, hospitals and academic research and was projectleader of several projects.
In 2013 Birgit started with the setup of the biology labs (molecular biology, microbiology and cell biology) at Chemelot Innovation and Learning Labs (CHILL). CHILL connects entrepreneurs, SMEs, large companies and research institutes, creating limitless opportunities for innovation. As a business development manager Birgit is responsible for the acquisition of new clients and for maintaining research output. Within the biology labs of CHILL Birgit works with a team of researchers, technicians and students on innovation projects from either companies (private projects) or knowledge institutes (public projects).


Healthcare associated infections (HCAI) are one of the most frequent occurring adverse effects in healthcare. They are important causes of morbidity and mortality and are associated with a substantial increase in healthcare costs each year. Research suggests that a large part of the HCAI are preventable. To reduce the risk of acquiring a HCAI the bacterial contamination needs to be reduced as far as possible. Especially since the number of infections with (multi)drug resistant (MDR) bacteria continues to increase at a significant rate. In order to reduce the risk of bacterial contaminations strict cleaning protocols have been introduced. In addition, there is more and more interest in the use of antibacterial materials. However, environmental hygiene monitoring is infrequently applied. One of the main reasons is that sensitive and quick methods for environmental monitoring of microbiological contaminations are lacking.
Conventional monitoring of microbiological contaminations largely relies on analysis by culturing on artificial growth media and/or microscopic assay. However, culturing methods are laborious and need a long analytical time. Additionally, they are imprecise as they do not detect nonculturable organisms and identification is generally limited to the genus level. This calls for techniques with an increased reliability, efficiency, and precision. At CHILL we work in Communities for Developments (CfD) on the development of assays for enhanced detection of surface-associated bacteria.
A state-of-the-art innovation to combat pathogenic bacteria is the creation of self-disinfecting surfaces through the application of coatings with bactericidal properties. These coatings are interesting in healthcare because of the capability to kill pathogens on contact. However, AMC will only enter the healthcare market and have an impact on hygiene and hospital acquired infections if their efficacy can be shown in appropriate (field) testing. CHILL and Zuyd University of Applied Sciences have initiated an applied research program of field based studies testing the efficacy of AMC in real life (healthcare) environments. The unique approach of so called Communities for Development combines applied research and education with business innovations and societal importance.

Tamar van Asch

14:30 - SensUs - The first international student competition on molecular biosensors for healthcare applications

Tamar van Asch

SensUs, NL



SensUs is the annual international competition in the field of molecular biosensors for healthcare applications (www.sensus.org) which is organized by honors students of Eindhoven University of Technology.

SensUs stimulates education and innovation in the field of molecular biosensing with a worldwide scope. Healthcare is developing toward highly personalized treatments, attuned to the needs of patients and based on real time, precise and reliable data. Important enablers are miniaturized and easy to use biochemical sensing devices called molecular biosensors. These measure molecules in body fluids. A well-known example is the blood glucose biosensor for patients with diabetes. Molecular biosensors include sensing systems for near-patient testing (point-of-care) as well as small systems that are worn on or in the body (in-vivo sensors). Biosensors can help doctors with monitoring, treatment and coaching of patients.

SensUs 2017 includes 10 student teams from universities in 9 countries (UK, Sweden, USA, Switzerland, Egypt, Germany, Belgium, Denmark, Netherlands). The teams are building biosensors for the detection of NT-proBNP, which is a key biomarker for heart failure. Heart failure is a very important public health problem in both developed and developing countries with a prevalence of about 1% of the population. The teams will all come to the biosensor contest in Eindhoven on 8 and 9 September 2017, where they will demonstrate their biosensors and will compete for different awards.

In this contribution, we will explain the goal, philosophy and planning of SensUs, we will describe the involvement of universities, companies, patient organizations and healthcare professionals, and we will show a short movie of SensUs 2016 and give an outlook toward SensUs 2018.

← back to program